Merck & Co., Inc. (MRK) — closed signal from August 21, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on November 19, 2025.
Predicted vs. what happened
What happened
Reached its target in 89 days.
The thesis — published August 21, 2025
Merck is a steady healthcare stock with a gentle uptrend. After six days of gains, the price paused, which can offer a better spot to buy. The sector looks cheap versus history, and new areas like dementia treatments are drawing attention. Keytruda and vaccines provide dependable cash flow. Over the next 0-3 months, consider buying small dips while staying mindful of policy changes and drug pipeline risks.
Primary drivers
- Six-day rise paused, offering a calmer dip to buy at a better price
- Trend signals look positive, suggesting the price could keep climbing
- Healthcare stocks look historically cheap, attracting fresh investor interest
- Growing dementia care needs may lift long-term demand for Merck products
How it played out
MRK: target reached in 89 days
Lyra published MRK at $84.60 on 2025-08-21, with 13% expected growth and a $93.86 target over a short-term window. The thesis pointed to a paused six-day rise, positive trend signals, historically cheap healthcare stocks, dependable Keytruda and vaccine cash flow, and growing dementia care needs.
Inside the window, MRK rose above the target. It peaked at $96.83 on 2025-11-18, with a 14.5% peak gain, and reached the target in 89 days. It ended at $94.24 on 2025-11-19, still above the target. The published thesis played out.
What happened during the window
On 2025-09-19, the FDA approved Keytruda Qlex for subcutaneous injection. On 2025-10-30, Investor's Business Daily reported that Merck topped third-quarter forecasts and raised its 2025 profit guidance, while Gardasil sales fell.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.